Corbus Pharmaceuticals (NASDAQ:CRBP) outlined a “catalyst-rich” 2026 at Oppenheimer’s 36th Annual Healthcare Conference, with Chief Executive Officer Yuval Cohen highlighting upcoming mid-year and ...

Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR ...

Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study Antibody-drug conjugates (ADCs) are ...

Bispecific antibodies (BsAbs) enhance NSCLC treatment by targeting dual antigens, improving efficacy, and overcoming resistance compared to conventional monoclonal antibodies. Amivantamab and ...

Antibody drugs such as monoclonal antibodies (mAb), bispecific antibodies, antibody-drug conjugates (ADCs), and nanobodies garnered increased interest in research and development circles. Sino ...

Grace Liu (left) is a Technical Account Manager at Sino Biological US Inc. (PA, USA). Grace joined Sino Biological in 2022, supporting CRO services and project management in the western and central US ...

Monoclonal antibodies (mAbs) bind to a variety of targets with high affinity and specificity, making them ideal therapeutics. However, traditional approaches to antibody screening workflows are labor ...

A lack of targeting specificity has been a long-running problem for cytotoxic anticancer agents, with excess side effects limiting their effectiveness. Scientists have turned to antibodies, and their ...

Zymeworks presents six posters at AACR highlighting advancements in antibody-drug conjugates and T cell engagers, including ZW209's promise in lung cancer. Zymeworks Inc. announced the presentation of ...